Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms

Fig. 5

a Flow cytometric analysis demonstrates that treatment of nude mice bearing an orthotopic neuroblastoma xenograft with intravenous DpC (4 mg/kg/day) administered via the tail vein over 3 weeks increases Annexin V and caspase 3 expression in the tumor, but not in b the lung. *p < 0.05 by an unpaired two-tailed Student’s t test in three nude mice after 21 days of DpC treatment. c, d Histopathological assessment (hematoxylin and eosin, H&E) of the tumor (c) and lung (d) after 3 weeks of intravenous treatment of mice with either the vehicle control or DpC (4 mg/kg/day). c H&E staining demonstrating a decrease in tumor cell infiltration after DpC treatment relative to the vehicle control and d evidence of exudative inflammation could be observed in lung tissue of nude mice following treatment with DpC relative to the control. The results in (a) and (b) are typical experiments from three performed. The results in (c) and (d) are typical photographs from sections of tissue. Scale bar on H&E photographs, 50 μm

Back to article page